Burden of community-acquired pneumonia in adults over 18 y of age

Abstract

This study aimed to determine the economic burden and affecting factors in adult community-acquired pneumonia (CAP) patients (≥ 18 years) by retrospectively evaluating the data of 2 centers in Istanbul province, Turkey. Data of outpatients and inpatients with CAP from January 2013 through June 2014 were evaluated. The numbers of laboratory analyses, imaging, hospitalization days, and specialist visits were multiplied by the relevant unit costs and the costs of the relevant items per patient were obtained. Total medication costs were calculated according to the duration of use and dosage. The mean age was 61.56 ± 17.87 y for the inpatients (n = 211; 48.6% female) and 53.78 ± 17.46 y for the outpatients (n = 208; 46.4% male). The total mean cost was €556.09 ± 1,004.77 for the inpatients and €51.16 ± 40.92 for the outpatients. In the inpatients, laboratory, medication, and hospitalization costs and total cost were significantly higher in those ≥ 65 y than in those <65 y. Besides the hospitalization duration, specialist visit, imaging, laboratory, medication, and hospitalization costs and total cost were significantly higher in those hospitalized more than once than in those hospitalized once. While the specialist visit cost was higher in the inpatients with comorbidities, the imaging cost was higher in the outpatients with comorbidities. CAP poses a higher cost in inpatients, elders, and individuals with comorbidities. Costs can be decreased by rational decisions about hospitalization and antibiotic use according to the recommendations of guidelines and authorities. Vaccination may decrease medical burden and contribute to economy by preventing the disease, especially in risk groups.

Clinical and economic burden of infections in hospitalized solid organ transplant recipients compared with the general population in Canada – a retrospective cohort study

“…Moreover, we chose only three infectious syndromes and did not assess the outpatient costs associated with them. We would argue that these three diagnoses will constitute the majority of infectious syndromes as reported previously , and that inpatients costs exceed the out patients costs . Additionally, our analysis excluded the provinces of Manitoba and Quebec, and all Canadian territories since their data were not available to us, representing about 27% of the Canadian population.…”

Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials

“…The healthcare costs associated with pneumonia are high and represent a large economic burden [3, 11–16]. Furthermore, the costs associated with pneumonia increase substantially in elderly patients or those with a chronic or immunocompromising disease, because of a longer duration of inpatient hospitalisation and need for management of underlying comorbidities [11, 13, 17]. Clearly, it is therefore important to ensure that first-line treatment options for high-risk patients with pneumonia are effective in both improving patient outcomes and minimising the burden of pneumonia on the healthcare system.…”

Pneumococcal Vaccine as One of the Immunization Coverage Targets For Adulthood Vaccines: A Consensus Report of the Study Group For Adult Immunization of the Turkish Society of Clinical Microbiology and Infectious Diseases

“…Yine TGP olgularının ekonomik yükünü araştıran bir başka çalışmada, toplam maliyet, yatan hastalar için ortalama 556.09 ± 1004.77 € olarak; ayaktan izlenen hastalar için de ortalama 51.16 ± 40.92 € olarak hesaplanmıştır (31).…”